Providing quality, safe vaccines top priority: Bharat Biotech & Serum Institute in joint pledge
Hyderabad-based Bharat Biotech and the Serum Institute of India (SII), Pune, have jointly pledged a smooth rollout of and global access to their COVID-19 vaccines Covaxin and Covishield, respectively.
By Newsmeter Network Published on 5 Jan 2021 10:23 AM GMT
Hyderabad: Hyderabad-based Bharat Biotech and the Serum Institute of India (SII), Pune, have jointly pledged a smooth rollout of and global access to their COVID-19 vaccines Covaxin and Covishield, respectively.
Adar Poonawalla, the CEO of SII, and Krishna Ella, the MD of Bharat Biotech, in a joint statement said, "We are fully aware of the importance of vaccines for people and countries alike. We hereby communicate our joint pledge to provide global access to our COVID-19 vaccines."
In the statement, they also said saving lives and livelihoods of people in India and the world is the most important task. Vaccines are a global public health product and they have the power to save lives and accelerate the return to economic normalcy at the earliest, they said.
"Now the two COVID-19 vaccines have been issued emergency use authorisation in India, the focus is on manufacturing and supply and distribution so that populations that need it the most receive high quality, safe, and efficacious vaccines. Both our companies are fully engaged in this activity and consider it our duty to the nation and the world at large to ensure a smooth rollout of vaccines," they added.
